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Abstract. Antibiotic resistance is one of the most relevant problems in the healthcare: the growth 
of resistant microorganisms in healthcare settings is a worrisome threat, raising length to stay 
(LOS), morbidity and mortality in those patients.  
The importance of the antibiotic resistance and its spread around the world, gave rise to the 
activation of several surveillance systems, based especially on the collection of laboratory data to 
local or national level. 
The objective of this work is to carry out a review of the scientific literature existing on the topic 
and scientific activities related to surveillance of antibiotic resistance in the countries bordering 
the Mediterranean Sea. 
Recent Data from European Centre for Disease Prevention and Control (November 2015) show, 
for different combinations bacterium-drug, an increase of resistance from North to South and 
from West to East of Europe. It is of particular concern the phenomenon of resistance carried 
out by some gram-negative, specifically Klebsiella pneumoniae and Escherichia coli to third-
generation cephalosporin, often combined in opposition to fluoroquinolones and 
aminoglycosides.  
Is particularly high the incidence of resistance to carbapenems by strains of Enterobacteriaceae 
(Klebsiella included). The resistance exerted by MRSA (Methicillin-resistant Staphylococcus 
aureus) continues to be relevant, albeit showing some decline in recent years. The incidence of 
resistance carried on by Streptococcus pneumoniae is stable and is mainly relevant to macrolides. 
Finally, a significant increase in recording relatively exercised by Enterococcus faecium to 
Vancomycin. 
Detecting, preventing, and controlling antibiotic resistance requires strategic, coordinated, and 
sustained efforts. It also depends on the engagement of governments, academia, industry, 
healthcare providers, the general public, and the agricultural community, as well as 
international partners. Committing to combating antibiotic-resistant microbes does support 
patient care, economic growth, agriculture, and economic and national security. 
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Introduction. Antibiotics are medicaments used for 
treating infections due to bacteria. 
Unfortunately, when bacteria are exposed to 
antibiotics can develop mechanisms to survive the 
action of those drugs. In this situation, antibiotics 
may be partially or utterly ineffective and illnesses 
could become arduously treatable and, in some 
cases, untreatable. 
The inappropriate and excessive use of this 
drugs is the leading cause of the enlargement of 
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the phenomenon. Antibiotic resistance is one of 
the most relevant problems in the healthcare: the 
growth of resistant microorganisms in healthcare 
settings is a worrisome threat, raising length to 
stay (LOS), morbidity and mortality in those 
patients.  
Antibiotic misuse includes: taking antibiotics 
when not needed; taking antibiotics through ways 
other than prescription; skipping doses; self-
medicating; antibiotic sharing; irregularities in the 
intervals of taking the drug.  
Inappropriate prescribing includes: unnecessary 
prescription; improper prescription of broad-
spectrum drugs; prescription of an unsuitable 
antibiotic; inadequate dosage and/or duration of 
therapy.  
Therefore, prevention of resistance is a key 
weapon. It is important to target therapeutic 
interventions, to review and to implement 
surveillance. 
The importance of the antibiotic resistance and 
its spread around the world, gave rise to the 
activation of several surveillance systems, based 
especially on the collection of laboratory data to 
local or national level. 
The objective of this work is to carry out a 
review of the scientific literature existing on the 
topic and scientific activities related to 
surveillance of antibiotic resistance in countries 
bordering the Mediterranean Sea. The 
Mediterranean basin includes some twenty 
countries with substantial differences regarding 
size, population, and culture. In addition, these 
countries have very different socio-economic 
conditions with marked differences between the 
European countries of Northern Mediterranean 
and African and Asian countries of South 
Mediterranean. Of course, health care is affected 
by these socio-economic situations and the 
European countries of the Mediterranean have a 
higher level health care. Despite this, the active 
exchange of people and goods between the 
countries of the Mediterranean has always 
influenced some interdependence concerning both 
infections and antibiotic resistance of bacteria. 
We tried to make an update of the existing data 
on the subject matter, using the most reliable 
sources (PUBMED).  
 
Methods. This work results from a thorough study 
of existing literature on surveillance data on 
antibiotic resistance in countries bordering the 
Mediterranean Sea. 
In particular, it compares the situation 
described by the most recent data available, with 
the situation instead drawn from data dating back 
to about a dozen years does. 
Until 2010, the working group leading the 
"ARMed (Antibiotic Resistance Surveillance and 
Control in the Mediterranean Region) project” 
(who started in 2003, financed by the European 
Commission’s Directorate General for Research) 
had conducted relevant and interesting scientific 
studies on surveillance of antibiotic resistance in 
the Mediterranean. The ARMed project 
investigated the epidemiology of antimicrobial 
resistance, as well as its contributory factors, in a 
number of countries in the southern and eastern 
Mediterranean region through the collection of 
comparable and validated data. The methods 
used to collect data were: susceptibility test from 
invasive isolates, structured questionnaires and 
structured interviews. 
The Global Antimicrobial Resistance 
Surveillance System (GLASS) is being launched 
by WHO and implemented in 2015 to support a 
standardized approach to the collection, analysis 
and sharing of data on AMR at a global level, in 
order to inform decision-making, drive local, 
national and regional action, and provide the 
evidence base for action and advocacy. GLASS 
aims to combine clinical, laboratory and 
epidemiological data on pathogens that pose the 
greatest threats to health globally. The GLASS 
manual details the proposed approach for the early 
implementation of the surveillance system, that 
focus on antibiotic-resistant bacteria, and outlines 
the flexible and incremental development of the 
system that incorporates over time lessons learned 
from the early implementation phase.
1
 
Antibacterial class and antibacterial agents 
evaluated by GLASS are shown in the table 1, 
available in the related Manual for Early 
Implementation.
2
 
Another source considered is EARS-Net, a 
European network of national surveillance systems 
that maintains a comprehensive monitoring and 
information system with European reference data 
on antimicrobial resistance for public health 
purposes. EARS-Net, coordinated from 2010 by 
the European Centre for Disease Prevention and 
Control, is the largest publicly funded surveillance 
system for antimicrobial resistance in the
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Table 1. Pathogen–antimicrobial combinations on which GLASS will gather data (Adapted by the Manual for Early Implementation, 
GLASS). 
 
a) The listed substances are priorities for surveillance of resistance in each pathogen, although they may not be first-line options for 
treatment. One or more of the drugs listed may be tested. 
b) One or more of the drugs listed may be tested in countries. S, I, R and nominator and denominator data for each shall be reported 
separately. 
c) Imipenem or meropenem is preferred to represent the group when available. 
d) Cefoxitin is a surrogate for testing susceptibility to oxacillin (methicillin, nafcillin); the AST report to clinicians should state 
susceptibility or resistance to oxacillin. 
e) Oxacillin is a surrogate for testing reduced susceptibility or resistance to penicillin; the AST report to clinicians should state reduced 
susceptibility or resistance to penicillin. 
 
European region. The results contribute to greater 
public awareness and scientific understanding of 
antimicrobial resistance and its importance in 
public health. Antimicrobial resistance in Europe 
is monitored by a network of national surveillance 
systems in the European countries. 
The national networks systematically collect 
data from clinical laboratories in their own 
countries and upload the data to a central database 
maintained at European Centre for Disease 
Prevention and Control (The European 
Surveillance System - TESSy). After uploading, 
each country approves its own data and the results 
are made available from the ECDC website.
3
 
In order to maintain and facilitate the data 
reporting, ECDC ensures: validation of data from 
antimicrobial susceptibility tests for seven 
important bacterial pathogens isolated from 
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patients with invasive infections; analysis of trends 
in the occurrence of antimicrobial resistance over 
time and in different countries and regions; EQA 
(External Quality Assessment) and protocols on 
testing methods to improve the consistency and 
quality of the data. 
Instead, ESAC-Net (formerly ESAC) is a 
Europe-wide network of national surveillance 
systems, providing European reference data on 
antimicrobial consumption. ESAC-Net collects 
and analyses data on antimicrobial consumption 
from EU and EEA/EFTA countries, both in the 
community and in the hospital sector.  
The coordination of ESAC-Net was transferred 
to the European Centre for Disease Prevention and 
Control in July 2011. 
The collected data are used to provide timely 
information and feedback to EU and EEA/EFTA 
countries on indicators of antimicrobial 
consumption. These indicators provide a basis for 
monitoring the progress of EU and EEA/EFTA 
countries towards the prudent use of 
antimicrobials.
4
 
 
Discussion. In July 2006 the working group 
leading the "ARMed project" has outlined the 
preliminary results of their work, referring in 
particular to antibiotic resistance in the 
southeastern Mediterranean. The results were as 
follows: sporadic reports from centers in the south 
and east of the Mediterranean have suggested that 
the prevalence of antibiotic resistance in this 
region appears to be considerable, yet pan-regional 
studies using comparable methodology have been 
lacking in the past. Susceptibility test results from 
invasive isolates of Staphylococcus aureus, 
Streptococcus pneumoniae, Escherichia coli, 
Enterococcus faecium and faecalis routinely 
recovered from clinical samples of blood and 
cerebrospinal fluid within participating 
laboratories situated in Algeria, Cyprus, Egypt, 
Jordan, Lebanon, Malta, Morocco, Tunisia and 
Turkey. The samples, collected as part of 
the ARMed project Preliminary data in the first 
two years of the project, showed the prevalence of 
penicillin non-susceptibility in Streptococcus 
pneumoniae ranging from 0% (Malta) to 36% 
(Algeria) [median: 29%], whilst methicillin 
resistance in Staphylococcus aureus varied from 
10% in Lebanon to 65% in Jordan [median: 43%]. 
Country specific significant resistance in 
Escherichia coli was also investigated. 72% of 
isolates reported from Egyptian hospitals was 
resistant to third generation cephalosporins and 
40% was non-susceptible to fluoroquinolones in 
Turkey. Vancomycin non-susceptibility was 
reported only in 0.9% of Enterococcus faecalis 
isolates from Turkey and in 3.8% of Enterococcus 
faecium isolates from Cyprus. The preliminary 
results from the ARMed project appear to support 
previous sporadic reports suggesting high 
antibiotic resistance in the Mediterranean region. 
They suggest that this is particularly the case in 
the eastern Mediterranean region where resistance 
in Staphylococcus aureus and Escherichia. coli 
seems to be higher than that reported in the other 
countries of the Mediterranean.
5
 
A publication of March 2007 reports the results 
of a survey of infection control infrastructure in 
selected southern and eastern Mediterranean 
hospitals. A structured questionnaire concerning 
hospital infection control (IC) organization and 
initiatives was sent to 45 hospitals in Algeria, 
Cyprus, Egypt, Jordan, Lebanon, Libya, Malta, 
Morocco, Tunisia and Turkey. Hospitals bordering 
the eastern Mediterranean appeared to have more 
established IC infrastructures than southern 
Mediterranean hospitals. However, there were no 
significant differences among hospitals in the two 
regions in surveillance activities, the presence of 
an antibiotic policy or feedback of resistance data 
to prescribers, all of which were at a low level. 
Only a minority of hospitals had published 
antimicrobial treatment guidelines or gave 
feedback on antimicrobial resistance data to 
prescribers.
6
 
A further relevant work by the same authors is 
that of December 2007 concerning the prevalence 
of methicillin-resistant Staphylococcus aureus 
(MRSA) in invasive isolates from southern and 
eastern Mediterranean countries. In this work, it 
appears that most of the countries in the 
Mediterranean region are experiencing a surge in 
MRSA infections. This requires a greater focus to 
identify relevant drivers of resistance and 
implement effective practices consistent especially 
with improved infection control and antibiotic 
consumption practices.
7
 
In August 2008, the same group addressed the 
issue of antimicrobial resistance in invasive strains 
of Escherichia coli from southern and eastern 
Mediterranean laboratories. From January 2003 to 
December 2005, 5091 susceptibility test results 
from invasive isolates of Escherichia coli, 
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collected from blood cultures and cerebrospinal 
fluid routinely processed within 58 participating 
laboratories, were investigated. These laboratories 
in turn serviced 64 hospitals in Algeria, Cyprus, 
Egypt, Jordan, Lebanon, Malta, Morocco, Tunisia 
and Turkey. The median proportion of resistance 
to third-generation cephalosporins for the duration 
of the project was 18.9% (interquartile range 
(IQR): 12.5-30.8%), and for fluoroquinolones 
21.0% (IQR: 7.7-32.6%). A substantial proportion 
of strains reported by laboratories in countries east 
of the Mediterranean exhibited evidence of 
multiresistance, the highest percentage being from 
Egypt (31%).
8
 
In October 2008, the same working group 
described the characteristics of antibiotic 
consumption in southern and eastern 
Mediterranean hospitals. Emphasis on wide-
spectrum agents could explain one possible factor 
behind the documented high prevalence of 
resistance in important pathogens within these 
same hospitals and suggests the need for improved 
antibiotic stewardship and prescribing programs, 
which may well apply to the whole region.
9
 
In November 2008, the same group has drawn 
up a work concerning the Infection control and 
antibiotic stewardship practices reported by south-
eastern Mediterranean hospitals. The prevalence of 
multiple resistant organisms (MROs) reported 
from south-eastern Mediterranean hospitals 
highlights the need to identify possible 
contributory factors to help design control 
interventions. This aspect was investigated 
through a structured questionnaire, which 
examined infection control and antibiotic 
stewardship practices in hospitals participating or 
collaborating with the Antibiotic Resistance 
Surveillance & Control in the Mediterranean 
Region (ARMed) project.  
A total of 45 hospitals (78.9% of invited 
institutions) responded to the questionnaire; 60% 
indicated that they faced periods of overcrowding 
when available bed complement was insufficient 
to cope with hospital admissions and 62% reported 
difficulties in isolating patients with MROs due to 
lack of available beds. Most hospitals relied 
mainly on washing to achieve hand hygiene, 
whether by non-medicated or disinfectant soaps. 
Dependence on solid bars of soap (28.9%) and 
cloth towels (37.8%) were among the problems 
identified as well as inconvenient distances of 
sinks from patient beds (66.6%). Alcohol hand rub 
was the effective hand hygiene product in only 7% 
of hospitals. Programs for better antibiotic use 
were mostly limited in scope; 33.3% reported 
having antibiotic prescribing guidelines, and 
53.3% of hospitals fed back resistance rates to 
prescribers. Auditing of antibiotic consumption, 
whether institution- or unit-based, was carried out 
in 37.8% of responding hospitals. Multi-faceted 
approaches to improving the isolation of patients 
with ORP, increasing the emphasis on hand 
hygiene, encouraging greater use of alcohol hand 
rubs and the introduction of effective antibiotic 
management programs should be more widespread 
in southeastern Mediterranean hospitals.
10
 In 
January 2009, this working group has studied the 
correlation between methicillin-resistant 
Staphylococcus aureus prevalence and infection 
control initiatives within southern and eastern 
Mediterranean hospitals. The Mediterranean 
region has been identified as an area of 
hyperendemicity for multi-resistant hospital 
pathogens. To better understand the potential 
drivers behind this situation, the group attempted 
to correlate the previously published methicillin-
resistant Staphylococcus aureus (MRSA) data 
from 27 hospitals, participant in the Antibiotic 
Resistance Surveillance & Control in the 
Mediterranean Region (ARMed) project, with the 
responses received from the same institutions to 
questionnaires which dealt with various aspects of 
infection control and antibiotic stewardship. No 
difference in the scores replies to structured 
questions regarding infection control set-up, hand 
hygiene facilities and antibiotic stewardship 
practices could be ascertained between hospitals 
with a high or low prevalence of infections. 
However, the group did identify differences 
concerning bed occupancy and isolation facilities. 
Hospitals reporting frequent episodes of 
overcrowding, particularly involving several 
departments, and which found persistent 
difficulties in sourcing isolation beds, had 
significantly higher MRSA proportions. This 
suggests that infrastructural deficits related to 
insufficient bed availability and compounded by 
inadequate isolation facilities could potentiate 
MRSA hyperendemicity in south-eastern 
Mediterranean hospitals.
11
 
In 2009, the same group described the role of 
the Self-medication with antibiotics in the 
ambulatory care setting within the Euro-
Mediterranean region. Anecdotal data from the 
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southern and eastern Mediterranean region 
suggests that self-medication with antibiotics is 
commonly practiced in many countries. Thus, non-
prescribed antibiotic use is high within ambulatory 
care in the south and east Mediterranean countries, 
being almost twice that reported in a similar 
European study. Corrective efforts are clearly 
required in the region to ensure proper use of 
antimicrobials so as to reduce pressure for 
antimicrobial resistance. In order to provide 
adequate information on the situation, the group 
undertook short structured interviews in out-
patients clinics or primary health centers in 
Cyprus, Egypt, Jordan, Lebanon, Libya, Tunisia 
and Turkey. A total of 2109 interviews were 
undertaken of which 1705 completed the full 
questionnaire. Self-medication was reported by 
19.1% (<0.1% in Cyprus to 37% in Lebanon) of 
respondents. Intended self-medication ranged from 
1.3% (95% CI 0%, 3%) in Cyprus to 70.7% (95% 
CI 64%, 77%) in Jordan. Upper respiratory tract 
symptoms were the most frequent reasons for 
which respondents indicated they would self-
medicate. 48.4% of the whole group replied that 
they kept antibiotics at home, being highest in 
Lebanon (60%, 95% CI 51%, 69%). The group 
found a significant association between antibiotic 
hoarders and intended users of antibiotics for self-
medication.
12
 
In March 2009 the same group described the 
prevalence of penicillin and erythromycin 
resistance among invasive Streptococcus 
pneumoniae isolates reported by laboratories in the 
southern and eastern Mediterranean region. 
Information about the epidemiology of resistance 
in Streptococcus pneumoniae within these 
countries of the Mediterranean region is 
incomplete, as reports have been sporadic and 
difficult to compare. ARMed data on the 
antimicrobial resistance epidemiology of 
Streptococcus pneumoniae in the southern and 
eastern Mediterranean region provided evidence of 
high rates of resistance, especially to penicillin. 
This evidence calls for a greater focus on the 
identification of relevant drivers of resistance and 
on the implementation of effective practices to 
address this problem. Over a 36-month period, 
from 2003 to 2005, the ARMed project collected 
1298 susceptibility test results of Streptococcus 
pneumoniae invasive isolates from blood and 
spinal fluid cultures routinely processed within 59 
participating laboratories situated in Algeria, 
Cyprus, Egypt, Jordan, Lebanon, Malta, Morocco, 
Tunisia and Turkey. Overall, 26% (335) of isolates 
were reported as non-susceptible to penicillin, 
with the highest percentages being reported from 
Algeria (44%) and Lebanon (40%). During the 
same period, the highest proportions of 
pneumococci that were not susceptible to 
erythromycin were reported from Malta (46%) and 
Tunisia (39%). Dual non-susceptibility 
proportions more than 5% were found in 
laboratories of Algeria, Tunisia, Lebanon, Jordan 
and Turkey.
13
 
Some consideration and conclusion have been 
drawn from the ARMed project throughout the 
years. The consensus conference held in Malta in 
November 2006 provided a forum for expert 
delegates to agree on some priority strategic 
recommendations that would be relevant to 
resistance containment efforts in the region. There 
was general agreement on the need for 
surveillance and audit to underpin any intervention 
to tackle antimicrobial resistance, both to monitor 
changing epidemiological trends in critical 
pathogens as well as to identify antibiotic 
consumption practices and effectiveness of 
prevention and control of health care-associated 
infections. In October 2009, the working group 
reported the Consensus Conference of the 
Antibiotic Resistance Surveillance and Control 
Group in the Mediterranean region. Antimicrobial 
resistance was considered a global threat to 
effective health care delivery. However the case in 
the Mediterranean area the data from recent 
studies suggested a situation of overwhelming 
danger. A better knowledge base, as well as a 
collaborative effort, was therefore required to 
address this increasing challenge to an effective 
patient care. The importance to convey these data 
to key users was also stressed in all workshops, as 
was better education of patients and training of 
health care workers. The recommendations also 
made it clear that ownership of the problem needs 
to be improved throughout the involvement of 
single regions and nations and that specific 
resources, both financial as well as human, must 
be allocated by the respective policy makers to 
counteract it.
14
 
In April 2010 the working group has drawn up 
a work concerning Antibiotic consumption as a 
driver for resistance in Staphylococcus aureus and 
Escherichia coli within a developing region. The 
results suggest an association between resistance 
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and antibiotic use, especially for carbapenems and 
a third-generation cephalosporin. These data 
support the urgent implementation of antibiotic 
stewardship initiatives in hospitals in developing 
countries that focus on a more judicious use of 
broad-spectrum formulations.
15
 
In addition, in 2012 the European Centre for 
Disease Prevention and Control (ECDC) launched 
the ‘European survey of carbapenemase-producing 
Enterobacteriaceae (EuSCAPE)’ project to gain 
insights into the occurrence and epidemiology of 
carbapenemase-producing Enterobacteriaceae 
(CPE), to increase the awareness of the spread of 
CPE, and to build and enhance the laboratory 
capacity for diagnosis and surveillance of CPE in 
Europe. Data collected through a post-EuSCAPE 
feedback questionnaire in May 2015 documented 
improvement compared with 2013 in capacity and 
ability to detect CPE and identify the different 
carbapenemases genes in the 38 participating 
countries, thus contributing to their awareness of 
and knowledge about the spread of CPE. Over the 
last two years, the epidemiological situation of 
CPE worsened, in particular with the rapid spread 
of carbapenem-hydrolysing oxacillinase-48 
(OXA-48)- and New Delhi Metallo-beta-lactamase 
(NDM)-producing Enterobacteriaceae. In 2015, 
13/38 countries reported inter-regional spread of 
or an endemic situation for CPE, compared with 
6/38 in 2013. Only three countries replied that 
they had not identified one single case of CPE. 
The ongoing spread of CPE represents an 
increasing threat to patient safety in European 
hospitals, and a majority of countries reacted by 
establishing national CPE surveillances systems 
and issuing guidance on control measures for 
health professionals. However, 14 countries still 
lacked specific national guidelines for prevention 
and control of CPE in mid-2015.
16
 
ECDC (European Centre for Disease 
Prevention and Control) in November 2015 has 
published a report on the supervision on antibiotic 
resistance in the year 2014. For different 
combinations bacterium-drug reported an increase 
of resistance as you move from North to South and 
from West to East of Europe; This is due to the 
differences between the different zones, the 
appropriateness of the use of antibiotics and health 
care practices, as well as in the effectiveness of 
infection control.  
The phenomenon of resistance presented by 
some gram-negative, specifically focusing on 
resistance of Klebsiella pneumoniae and 
Escherichia coli to third-generation 
cephalosporins, often combined in opposition to 
fluoroquinolones and aminoglycosides, appears 
very dangerous. It can lead to an increased use of 
carbapenems which can in turn promote resistance 
to this class of antibiotics: this has been 
highlighted much more to Klebsiella pneumoniae. 
In fact, from the data available, is particularly 
relevant the incidence of resistance to 
carbapenems by the strains of Enterobacteriaceae 
(Klebsiella included). Manufacturer of 
carbapenemase.  
Carbapenem resistance is also common 
(together with opposition to groups of antibiotics) 
on Pseudomonas aeruginosa and Acinetobacter 
spp. In these cases, treatment options include the 
use of drug combinations and the use of old 
antibiotics like polymyxin and colistin (to which 
are still common strengths, particularly the first). 
The resistance exerted by gram-positive shows 
a more mixed picture. The resistance exerted by 
MRSA (Methicillin-resistant Staphylococcus 
aureus) continues to be relevant, albeit showing 
some decline in recent years whereas that carried 
on by Streptococcus pneumoniae is stable and is 
mainly relevant to macrolides. Finally, it is 
significant the increase of resistance exercised by 
Enterococcus faecium to Vancomycin. The 
situation in Europe concerning combined 
resistances exerted by certain bacteria, are shown 
in Figures 1, 2, 3 and 4.
17
 It is clear that, from this 
point of view, the situation in Northern Europe is 
better than that of the countries bordering the 
Mediterranean, with particular reference to what 
concerns Escherichia coli, Klebsiella pneumoniae, 
Pseudomonas aeruginosa and Acinetobacter spp. 
 
Conclusions. In May 2015, the Sixty-eighth 
World Health Assembly (the decision-making 
body of WHO) adopted the global action plan on 
antimicrobial resistance. One of the five strategic 
objectives of the action plan is to strengthen the 
evidence base through enhanced global 
surveillance and research.
1
 
 Antimicrobial resistance (AMR) surveillance is 
the cornerstone for assessing the burden of AMR 
and for providing the necessary information for 
action in support of local, national and global 
strategies. The Global Antimicrobial Resistance 
Surveillance System (GLASS) is being launched 
to support a standardized approach to the 
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collection, analysis and sharing of data on AMR at 
a global level, to inform decision-making, drive 
local, national and regional action, and provide the 
evidence base for action and advocacy.  
Countries can benefit from participation in 
GLASS through enhanced capacity building, 
access to training and implementation tools, and 
support in collecting AMR data at local and 
national levels. Country participation in GLASS 
must be with the agreement of the national 
government. 
Early implementation of GLASS is based on 
this type of surveillance. A benefit of the 
monitoring approach proposed in GLASS is that
 
Figure 1. (Antimicrobial resistance surveillnace in Europe, Surveillance report, ECDC, 2014). Escherchia coli. Percentage (%) of invasive 
isolate with combined resistance to third generation cephalosporin, fluorochinolones and aminoglycosides, by country,EU/EEA 
countries,2014 
 
Figure 2. (Antimicrobial resistance surveillnace in Europe, Surveillance report, ECDC, 2014). Klebsiella pneumoniae Percentage (%) of 
invasive isolates with combined resistance to fluoroquinolones, third generation cephalosporins and aminoglycosides, by countries, 2014. 
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Figure 3. (Antimicrobial resistance surveillnace in Europe, Surveillance report, ECDC, 2014). Pseudomonas aeruginosa. Percentage (%) of 
invasive isolates with combined resistance (resistance to three or more antimicrobial groups among piperacillin + tazobactan, ceftazidime, 
fluoroquinolones, amynoglycosides and carbapenems), by country, EU/EEA countries, 2014. 
 
 
Figure 4. (Antimicrobial resistance surveillnace in Europe, Surveillance report, ECDC, 2014). Acinetobacter spp. Percentage (%) of invasive 
isolates with combined resistance to fluoroquinolones, aminoglycosides and carbapenens, by country, EU/EEA countries, 2014. 
 
epidemiological and clinical data are combined 
with microbiological data. This system allows 
stratification of populations to ascertain e.g. the 
most frequent type of resistant infection, the age 
structure of infections, whether most occur in the 
community or hospital and the geographical 
distribution. This method has also drawbacks. 
Although infections due to bacteria resistant to 
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antimicrobial agents do not usually present 
differently from those due to the same but 
susceptible bacteria, in the settings where samples 
are not routinely sent for microbiological 
investigation, those examined are more likely to be 
taken from severely ill patients who have failed 
first- and perhaps second-line treatment. This type 
of surveillance is therefore more likely to find 
resistant strains. Despite these caveats, data from 
surveillance based on routinely collected clinical 
samples can be used for several purposes if core 
data are collected both on patients and the 
population from which they derive and if 
duplicated results for the same patient are 
removed: 
- A combination of epidemiological and 
laboratory data allows stratification of populations 
for ascertaining the type of infection, whether 
most AMR infections are occurring, e.g. in young 
or elderly people, in the community or hospital, 
and reporting the geographical distribution of 
infections caused by resistant organisms; 
- The extent of AMR infections can be assessed 
from epidemiological indicators such as incidence 
and prevalence. Epidemiological and laboratory 
data must represent a defined population to be 
pertinent. For infections of hospital origin, the 
most common denominator is the number of 
hospital admissions or patient-days in the hospital. 
The population denominator for assessing 
infections occurring in the community may be 
difficult to determine, as it requires counting the 
number of infections in a population in a specified 
catchment area. However, it is crucial for 
understanding variations in sampling frequency 
and impact of resistant infections; 
- Routine data from antibiograms can be 
analyzed for new trends by comparing them with 
data from the previous year, to determine any 
significant change in important resistant bacteria, 
such as carbapenem-resistant Enterobacteriaceae. 
Information on any increase is critical for 
designing local measures to prevent transmission 
of resistant bacteria; a decrease may reflect an 
impact of interventions. As one of the objectives 
of early implementation is to build common 
understanding by testing the feasibility of 
collecting and sharing harmonized data, the 
limitations of surveillance based on routinely 
collected clinical samples is not considered to be a 
major problem at this stage.
2
 
In reference to the prospects, the World 
Alliance Against Antibiotic Resistance (WAAAR) 
is a nonprofit organization open to professionals 
and consumers worldwide. It constitutes a group 
of 700 individuals from 55 different countries 
representing all the key stakeholders (physicians, 
veterinarians, microbiologists, surgeons, 
pharmacists, nurses, evolutionary biologists, 
ecologists, environmentalists, and patient 
advocacy groups). The Alliance receives support 
from more than 140 scientific societies or 
professional groups throughout the world.
18
 
The cost of antimicrobial resistance (AMR) 
entails 300 million premature deaths (every year: 
390.000 deaths in Europe, 4.150.000 deaths in 
Africa, 4.730.000 in Asia) and up to $100 trillion 
(£64 trillion) lost to the global economy by 2050.
19
 
Detecting, preventing, and controlling antibiotic 
resistance requires strategic, coordinated, and 
sustained efforts. It also depends on the 
engagement of governments, academia, industry, 
healthcare providers, the general public, and the 
agricultural community, as well as international 
partners. Committing to combating antibiotic-
resistant microbes supports patient care, economic 
growth, agriculture, and economic and national 
security.
20
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